Development of a Novel Cytomegalovirus Drug

Cytomegalovirus (CMV) causes severe infections in infants, organ transplant recipients and AIDS patlong term objective of this work is to treat humans who have cytomegalovirus infections with a novelspecific aims of this grant are to perform animal pharmacology studies, including efficacy, pharmacodisposition, and toxicity studies in mice after intravenous or oral administration of the antiviralseveral drugs that are currently available for the treatment of CMV, these drugs often only delay thinduced pathology, cause serious toxicity, and are subject to the development of resistance. There idevelopment of more effective and novel drugs for the treatment of CMV. T01132 is a non-nucleoside capproximately ten times more potent than ganciclovir in vitro. It is believed to have a novel mechanagainst ganciclovir-resistant CMV, and exhibited low in vitro and in vivo toxicity in pilot experimeproperties, this compound may provide significant advantages over presently available drugs for thecytomegalovirus.